CalciMedica Receives Dual Nasdaq Delisting Notices for Low Market Value and Bid Price
CALC sits 73% above its 52-week low of $0.461 on light trading volume (0.3× avg).
Summary
CalciMedica, Inc. received notices from Nasdaq for non-compliance with both the minimum market value of listed securities and the minimum bid price requirements, initiating a 180-day period to regain compliance or face delisting.
Key Events · Legal and Risk Events · CALC
-
Nasdaq MVLS Non-Compliance
CalciMedica received a notice on March 13, 2026, for failing to maintain a market value of listed securities of at least $35,000,000 for 30 consecutive business days. The company also does not meet the stockholders' equity or net income requirements.
-
Nasdaq Minimum Bid Price Non-Compliance
On March 16, 2026, the company received a separate notice for its common stock trading below $1.00 per share for 30 consecutive business days.
-
Compliance Period Initiated
The company has 180 calendar days (until September 9, 2026, for MVLS and September 14, 2026, for bid price) to regain compliance with each Nasdaq listing rule.
-
Potential Reverse Stock Split
CalciMedica stated it will consider available options to regain compliance, including a reverse stock split.
Analysis · CALC · Life Sciences
This 8-K filing signals significant financial distress for CalciMedica, as it has received dual delisting notices from Nasdaq. The company is non-compliant with the minimum market value of listed securities ($35M) and the minimum bid price ($1.00), and also fails to meet stockholders' equity and net income standards. While the company has 180 days to regain compliance, the substantial gap to the $35M market value requirement and the need for a significant stock price increase highlight the severity of the situation. The mention of a potential reverse stock split indicates the company is considering drastic measures, which often precede further stock price volatility and can be dilutive. Investors should view this as a critical risk to the company's public listing and long-term viability.
At the time of this filing, CALC was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.